Outset Medical (NASDAQ:OM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Outset Medical (NASDAQ:OM) from a sell rating to a hold rating in a report published on Saturday morning.

OM has been the subject of several other research reports. TD Cowen reiterated a “buy” rating on shares of Outset Medical in a research report on Friday, May 8th. Weiss Ratings upgraded Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Outset Medical currently has an average rating of “Hold” and a consensus price target of $10.00.

Outset Medical Price Performance

Shares of Outset Medical stock opened at $4.51 on Friday. The stock has a market capitalization of $84.79 million, a price-to-earnings ratio of -1.10 and a beta of 1.96. The firm’s 50-day moving average price is $4.58 and its two-hundred day moving average price is $4.24. The company has a current ratio of 5.19, a quick ratio of 4.11 and a debt-to-equity ratio of 1.03. Outset Medical has a 1-year low of $3.00 and a 1-year high of $16.16.

Outset Medical (NASDAQ:OM) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The firm had revenue of $31.64 million during the quarter, compared to the consensus estimate of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. On average, equities analysts predict that Outset Medical will post -3.9 earnings per share for the current fiscal year.

Insider Activity at Outset Medical

In other news, CFO Renee Gaeta sold 17,672 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68. Following the sale, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at $561,939.82. This represents a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc bought a new position in Outset Medical in the 2nd quarter valued at $34,000. BNP Paribas Financial Markets raised its position in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares during the last quarter. New York State Common Retirement Fund bought a new stake in shares of Outset Medical during the second quarter worth $108,000. Los Angeles Capital Management LLC acquired a new position in shares of Outset Medical during the fourth quarter valued at $29,000. Finally, Quantbot Technologies LP acquired a new position in shares of Outset Medical during the second quarter valued at $152,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.